What does Relmada Therapeutics, Inc. do?
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive…
What is Relmada Therapeutics, Inc.'s P/E and P/B ratio?
Relmada Therapeutics, Inc. has a P/E ratio of -3.6 and a P/B ratio of 1.70.
What is Relmada Therapeutics, Inc.'s debt-to-equity ratio?
Relmada Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Relmada Therapeutics, Inc. owe compared with what it owns?
Relmada Therapeutics, Inc. owes $0.06 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Relmada Therapeutics, Inc.'s Positivity rank?
Relmada Therapeutics, Inc. is ranked #2,699 of 6,774 companies globally and #938 of 4,000 in United States on PositoAI, with a Positivity Score of 21,220.
Does Relmada Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Relmada Therapeutics, Inc..
Where can I read the latest news about Relmada Therapeutics, Inc.?
Recent headlines about Relmada Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Relmada Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Relmada Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.